Loading...
NPI 1245249689 · Henderson, NV · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Rupesh Parikh is a hematology & oncology physician provider located in Henderson, Nevada. This profile covers 101 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Rupesh Parikh |
| Address | 10001 S Eastern Ave Ste 108 |
| City | Henderson |
| State | NV |
| ZIP | 89052 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | August 5, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.1M |
| Medicaid | $9.6K |
This provider’s billing is overwhelmingly Medicare-driven: Total Medicare revenue is $3.1M versus total Medicaid revenue of $9.6K, so Medicaid represents only a token share of reported public-payer revenue. All Medicaid revenue is concentrated in a single code (99214) and the Medicaid footprint is effectively modest compared with the provider’s scale on Medicare.
Revenue concentration on Medicare is highly concentrated: the precomputed top three Medicare codes account for 72.5% of the provider’s total Medicare revenue, led by J9271 at 58.1% of Medicare revenue, followed by J0897 (8.5%) and J1568 (5.9%). This concentration indicates that a small set of high-cost injectable biologics and immunologic products drive the majority of billed Medicare dollars.
The CPT/HCPCS mix is consistent with an infusion-centered hematology/oncology practice: dominant use of J9271 (pembrolizumab), significant denosumab (J0897) and IV immune globulin (J1568), alongside chemotherapy administration codes such as 96413 and 96417 and infusion initiation code 96365. High volumes of drug administration codes plus supportive infusible agents suggest the practice delivers in-office oncologic biologic and chemotherapy treatments rather than purely consultative visits.
For pembrolizumab (J9271) the provider is a major national administrator: J9271 is reported at $1.6M (58.1% of Medicare revenue) and ranks #34 of 1841 providers nationally (98th percentile), described as notably above typical national volume. This ranking places the provider among the top-tier national deliverers of that specific immunotherapy product.
Office evaluation-and-management volume is unusually large for a specialty practice: 99214 appears with 1.5K Medicare claims ($139.8K) and ranks #3813 of 479517 providers nationally (99th percentile), labeled an extreme outlier, and 99215 is likewise in the 99th percentile. Those high E&M volumes imply substantial ongoing patient follow-up and management activity, suggesting steady longitudinal care and frequent visit-based encounters in addition to infusion services.
Multiple administration and ancillary service codes sit well above typical peer volumes, supporting the view of an on-site infusion operation: 96413 ranks in the 96th percentile (notably above typical), 96417 and 96375 are also described as notably above typical national volume, and phlebotomy (36415) ranks in the 99th percentile. In parallel, common lab panels and tests such as 80053, 85025, 82306 and 82784 register at high national percentiles, indicating substantial in-office or closely integrated lab work.
Despite very large Medicare activity, the provider is only a modest participant in Medicaid: all Medicaid revenue ($9.6K) comes from 99214 (112 claims) and the provider’s in-state rank on that code is #1531 of 2254 providers (32nd percentile), characterized as a typical, unremarkable volume in the state. This pattern implies limited engagement with the Medicaid population relative to Medicare.
The provider has an established billing history, with NPI enumerated on 2006-08-05 (~20 years ago). That tenure is consistent with a mature oncology practice able to support the high Medicare infusion volumes and the mix of E&M and ancillary services reported here.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
101 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 38,610 | $40 | $1.6M |
| J0897 | Injection, denosumab, 1 mg | 13,200 | $20 | $237.6K |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 4,880 | $30 | $165.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,470 | $100 | $139.8K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 620 | $140 | $84.3K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 41,700 | $1 | $83.4K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 700 | $100 | $72.7K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,920 | $20 | $67.2K |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 2,490 | $20 | $57.3K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 25,500 | $1 | $25.5K |
Showing 1–10 of 101
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 101 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
101 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 1 | 40 | 13,000 | $40 | $625.8K |
| J1568 | 6 | 10 | 4,470 | $30 | $164.2K |
| J0897 | 5 | 70 | 3,630 | $20 | $94.6K |
| Q5118 | 1 | 10 | 2,490 | $20 | $56.8K |
| J0881 | 5 | 30 | 17,400 | $1 | $49.5K |
| Q5119 | 1 | 10 | 2,050 | $20 | $46.4K |
| 82306 | 4 | 30 | 80 | $30 | $41.9K |
| 80061 | 19 | 50 | 60 | $10 | $32.8K |
| J1439 | 4 | 10 | 24,000 | $1 | $27.7K |
| J9217 | 23 | 40 | 120 | $130 | $23.9K |
Showing 1–10 of 101
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 110 | $90 | $9.6K |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,531 | 2,250 | 290 | $60 | $138K |
Other providers in the same ZIP code as Rupesh Parikh, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.